Hemophilia Qui Tam Suit Is Barred By Earlier Action, Judge In Drug Price Case Says

Hemophilia Qui Tam Suit Is Barred By Earlier Action, Judge In Drug Price Case Says

BOSTON - The Massachusetts federal judge overseeing federal drug pricing litigation on May 31 denied a motion by two whistle-blowers to reopen a settled case involving hemophilia drugs made by Baxter Healthcare Corp., finding that a specialty pharmacy was the first to file allegations involving the drugs (In Re: Pharmaceutical Industry Average Wholesale Price Litigation, MDL Docket No. 1456, No. 01-12257, Subcategories No. 08-11200 and No. 10-11186, United States of America ex rel. Linette Sun, et al. v. Baxter Healthcare Corporation, United States of America ex rel. Ven-A-Care of the Florida Keys, Inc. v. Baxter Healthcare Corporation, D. Mass.; 2013 U.S. Dist. LEXIS 76750).

Find full version on lexis Advance®
Access this news story on lexis.com®